Skip to main
CATX

CATX Stock Forecast & Price Target

CATX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 40%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Perspective Therapeutics is positioned for success in the radiopharmaceutical industry due to its proprietary technology that precisely targets cancer cells using the alpha-emitting isotope Lead-212. The company has a robust pipeline with multiple Ph1/2a data readouts expected later this year and a well-capitalized balance sheet. Additionally, its vertically integrated distribution and manufacturing network provides a structural advantage over its competitors, de-risking clinical execution and eventual commercial launch. Risks to the company's valuation and price target include potential competition and reimbursement challenges.

Bears say

Perspective Therapeutics is a relatively new company and its leading programs are still in early stages, with regulatory discussions ongoing. The delay in data updates and projected commercial sales in the future may lead to continued uncertainty, making it difficult for the stock to gain momentum. Additionally, the company's limited financials and adjusted share count may impact its ability to bring its technology to market in a timely manner.

CATX has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 40% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Perspective Therapeutics Inc (CATX) Forecast

Analysts have given CATX a Buy based on their latest research and market trends.

According to 10 analysts, CATX has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Perspective Therapeutics Inc (CATX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.